RheumNow Podcast – Booster Shots for COVID (8.13.2021)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)
Dr Jack Cush reviews the news, journal reports and FDA approvals from the past week on RheumNow.com
Rheumatic Flares Uncommon After COVID Vax
MedPage Today
Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)
Dr Jack Cush reviews rheumatology and COVID news from the past week on RheumNow.com.
Shingles Risk with JAK Inhibitors and Other Biologics
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
DMARD Effects on COVID-19 Outcomes
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug
Potential Birth Defects with Hydroxychloroquine
Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.
ICYMI: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul
ACR Stands Against Insurer Mandated Infusion Locations
ACR
The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provid
RheumNow Podcast - Best of EULAR 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Israel provides COVID vaccine answers for rheumatic disease patients
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Social
The Origin Story: Women in Rheumatology--The XX Factor
When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field.
https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor.
Sign up to attend our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Reassuring data by Dr. Laurent Arnaud on HCQ
- arrhythmia risk from HCQ similar to general population
@RheumNow #RNL2023 https://t.co/vMDg2SlbJQ
Robert B Chao, MD @doctorRBC ( View Tweet )
2 years 8 months ago
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 8 months ago
Metanalysis of 25 studies, betw 1985 - 2021, showed US average annual visits for RA=5.25 for US rheums (vs 3.3 ex-US) & 4.8 US non-rheums. SLE=3.24 & 12.3 for US non-Rheums. FM=1.8 for US rheums & 0.4 vs ex-US Rheums. Rheum Visits Decreased 1982 to 2019 https://t.co/WIXDXUCG60 https://t.co/s7W9gcd5dd
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Metanalysis of 25 studies, betw 1985 - 2021, showed US average annual visits for RA=5.25 for US rheums (vs 3.3 ex-US) & 4.8 US non-rheums. SLE=3.24 & 12.3 for US non-Rheums. FM=1.8 for US rheums & 0.4 vs ex-US Rheums. Rheum Visits Decreased 1982 to 2019 https://t.co/5ugk34MJ3b https://t.co/NDMYZT7pil
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/gVw2tGKYNG https://t.co/ItIKB8MFTI
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 9 months ago
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years 10 months ago
